No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US Stock MarketDetailed Quotes
ARTL Artelo Biosciences
- 0.9476
- +0.0016+0.17%
Close Dec 20 16:00 ET
- 0.9500
- +0.0024+0.25%
Post 20:01 ET
3.06MMarket Cap-0.33P/E (TTM)
0.9501High0.9100Low35.35KVolume0.9400Open0.9460Pre Close32.91KTurnover1.10%Turnover RatioLossP/E (Static)3.23MShares1.750052wk High0.48P/B3.03MFloat Cap0.910052wk Low--Dividend TTM3.20MShs Float75.0000Historical High--Div YieldTTM4.24%Amplitude0.9100Historical Low0.9310Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Optimistic Buy Rating for Artelo Biosciences Based on Promising Developments in Cancer Anorexia Treatment
Artelo Biosciences Is Maintained at Buy by D. Boral Capital
Artelo Biosciences Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Artelo Biosciences Presents Phase 1 Data On ART27.13 For Cancer-Related Anorexia At International Conference, Highlighting Good Tolerability And Weight Stabilization Or Reversal In Two-Thirds Of Participants; Phase 2 Enrollment Ongoing In CAReS Trial
Artelo Biosciences Announces Presentation of Phase 1 Data With ART27.13 in Cancer-Related Anorexia
Heat List
US
Overall
Symbol
Price
% Chg
No Data